SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common
SOLANA BEACH, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that it has priced an underwritten public offering of 2,413,793 shares of its common stock at a price to
SAN DIEGO, CA, September 24, 2013 – Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the pricing of its initial public offering of 2,100,000 shares of its common stock at a public offering price of $12.00 per
SOLANA BEACH, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has completed a pre‑New Drug Application (NDA) meeting with the U.S.
Healthcare practitioner survey indicates physicians’ awareness and intent to prescribe newly-launched product SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (“Evoke” or the “Company”) (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
SOLANA BEACH, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that together with the research team at H.C. Wainwright & Co.
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
SOLANA BEACH, Calif. , Aug. 12, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001,
SAN DIEGO , Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an